Relay Therapeutics Inc
RLAY3.625USD
+0.265+7.89%
Market hours （ET）Quotes delayed by 15 min
618.00MMarket Cap
LossP/E TTM
More Details of Relay Therapeutics Inc Company
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company is focused on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The Company’s Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608, Lirafugratinib (RLY-4008), and Migoprotafib (GDC-1971). RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor. RLY-4008, is a potent, selective, and oral small molecule inhibitor of FGFR2, a receptor tyrosine kinase that is frequently altered in certain cancers. GDC-1971 is an inhibitor of Src homology region 2 domain-containing phosphatase-2 (SHP2), as a monotherapy in patients with advanced or metastatic solid tumors.
Company Info
Ticker SymbolRLAY
Company nameRelay Therapeutics Inc
IPO dateJul 16, 2020
CEODr. Sanjiv K. Patel, M.D.
Number of employees261
Security typeOrdinary Share
Fiscal year-endJul 16
Address60 Hampshire Street
CityCAMBRIDGE
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code02139
Phone16173708837
Websitehttps://relaytx.com/
Ticker SymbolRLAY
IPO dateJul 16, 2020
CEODr. Sanjiv K. Patel, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Mark Murcko, Ph.D.
Dr. Mark Murcko, Ph.D.
Independent Director
Independent Director
996.95K
--
Mr. Brian R. Adams
Mr. Brian R. Adams
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
178.96K
-10.01%
Mr. Peter (Pete) Rahmer
Mr. Peter (Pete) Rahmer
Chief Corporate Development Officer
Chief Corporate Development Officer
173.28K
-8.97%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
25.00K
--
Dr. Donald A. Bergstrom, M.D., Ph.D.
Dr. Donald A. Bergstrom, M.D., Ph.D.
President - Research and Development
President - Research and Development
--
--
Dr. Linda A. Hill, Ph.D.
Dr. Linda A. Hill, Ph.D.
Independent Director
Independent Director
--
--
Dr. Sanjiv K. Patel, M.D.
Dr. Sanjiv K. Patel, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Thomas (Tom) Catinazzo
Mr. Thomas (Tom) Catinazzo
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
--
--
Dr. Claire Mazumdar, Ph.D.
Dr. Claire Mazumdar, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Mark Murcko, Ph.D.
Dr. Mark Murcko, Ph.D.
Independent Director
Independent Director
996.95K
--
Mr. Brian R. Adams
Mr. Brian R. Adams
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
178.96K
-10.01%
Mr. Peter (Pete) Rahmer
Mr. Peter (Pete) Rahmer
Chief Corporate Development Officer
Chief Corporate Development Officer
173.28K
-8.97%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
25.00K
--
Dr. Donald A. Bergstrom, M.D., Ph.D.
Dr. Donald A. Bergstrom, M.D., Ph.D.
President - Research and Development
President - Research and Development
--
--
Dr. Linda A. Hill, Ph.D.
Dr. Linda A. Hill, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025Q1
FY2024
FY2024Q3
FY2023
FY2022
FY2021
FY2020
No Data
By RegionUSD
Name
Revenue
Proportion
United States
7.68M
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, May 18
Updated: Sun, May 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
SB Investment Advisers (UK) Limited
16.28%
Point72 Asset Management, L.P.
6.32%
BlackRock Institutional Trust Company, N.A.
6.29%
Commodore Capital LP
5.83%
The Vanguard Group, Inc.
5.47%
Other
59.81%
Shareholders
Shareholders
Proportion
SB Investment Advisers (UK) Limited
16.28%
Point72 Asset Management, L.P.
6.32%
BlackRock Institutional Trust Company, N.A.
6.29%
Commodore Capital LP
5.83%
The Vanguard Group, Inc.
5.47%
Other
59.81%
Shareholder Types
Shareholders
Proportion
Hedge Fund
33.84%
Investment Advisor
30.76%
Private Equity
17.05%
Investment Advisor/Hedge Fund
15.09%
Sovereign Wealth Fund
3.37%
Research Firm
2.12%
Individual Investor
1.48%
Venture Capital
0.96%
Family Office
0.37%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
457
180.97M
105.56%
-7.64M
2025Q1
473
175.15M
102.43%
-21.99M
2024Q4
463
170.97M
101.10%
-14.45M
2024Q3
455
166.81M
103.61%
+17.06M
2024Q2
434
132.20M
98.83%
-25.01M
2024Q1
423
138.51M
105.71%
-7.14M
2023Q4
410
132.38M
103.96%
-10.79M
2023Q3
396
136.20M
110.68%
-5.83M
2023Q2
397
136.32M
112.15%
-5.86M
2023Q1
398
137.34M
113.25%
-2.03M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
SB Investment Advisers (UK) Limited
27.90M
16.28%
--
--
Mar 31, 2025
Point72 Asset Management, L.P.
10.83M
6.32%
+9.23M
+579.77%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
10.79M
6.29%
-75.94K
-0.70%
Mar 31, 2025
Commodore Capital LP
10.00M
5.83%
+10.00M
--
May 08, 2025
The Vanguard Group, Inc.
12.08M
7.04%
-2.92M
-19.50%
Mar 31, 2025
Casdin Capital, LLC
9.10M
5.31%
+150.00K
+1.68%
Mar 31, 2025
Tang Capital Management, LLC
8.07M
4.71%
--
--
Mar 31, 2025
Bellevue Asset Management AG
7.38M
4.3%
--
--
Mar 31, 2025
Norges Bank Investment Management (NBIM)
5.78M
3.37%
+2.46M
+74.19%
Dec 31, 2024
State Street Global Advisors (US)
5.16M
3.01%
-120.53K
-2.28%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
0.9%
TrueShares Technology, AI & Deep Learning ETF
0.47%
Tema Oncology ETF
0.42%
ALPS Medical Breakthroughs ETF
0.4%
JPMorgan Fundamental Data Science Small Core ETF
0.18%
SPDR S&P Biotech ETF
0.16%
Direxion Daily S&P Biotech Bull 3X Shares
0.09%
Avantis US Small Cap Equity ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.07%
Invesco Nasdaq Biotechnology ETF
0.07%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.9%
TrueShares Technology, AI & Deep Learning ETF
Proportion0.47%
Tema Oncology ETF
Proportion0.42%
ALPS Medical Breakthroughs ETF
Proportion0.4%
JPMorgan Fundamental Data Science Small Core ETF
Proportion0.18%
SPDR S&P Biotech ETF
Proportion0.16%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.09%
Avantis US Small Cap Equity ETF
Proportion0.07%
ProShares Ultra Nasdaq Biotechnology
Proportion0.07%
Invesco Nasdaq Biotechnology ETF
Proportion0.07%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
